enGene (NASDAQ:ENGNW) Shares Up 5% – Should You Buy?

enGene (NASDAQ:ENGNW) Shares Up 5% – Should You Buy? Posted by Defense World Staff on Aug 12th, 2026 Share on Twitter Share on Facebook Share on LinkedIn Share on Stocktwits enGene Holdings Inc. ( NASDAQ:ENGNW – Get Free Report )’s stock price traded up 5% on Tuesday . The company traded as high as $0.48 and last traded at $0.5040. Approximately 250 shares changed hands during mid-day trading, a decline of 98% from the average daily volume of 16,253 shares. The stock had previously closed at $0.48. enGene Stock Up 5.0% The stock has a fifty day moving average of $0.30 and a 200-day moving average of $1.54. About enGene ( Get Free Report ) enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada. Further Reading Five stocks we like better than enGene Atlassian Just Pulled Off the Software Comeback Wall Street Wanted AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings Apple’s Next iPhone Could Test How Much Pricing Power Is Left Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter .